首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2441961篇
  免费   201774篇
  国内免费   4491篇
耳鼻咽喉   35041篇
儿科学   74689篇
妇产科学   64707篇
基础医学   344742篇
口腔科学   69030篇
临床医学   221455篇
内科学   485051篇
皮肤病学   49491篇
神经病学   207222篇
特种医学   98189篇
外国民族医学   912篇
外科学   368872篇
综合类   56572篇
现状与发展   1篇
一般理论   998篇
预防医学   197192篇
眼科学   56614篇
药学   182396篇
  4篇
中国医学   4593篇
肿瘤学   130455篇
  2018年   27740篇
  2017年   21004篇
  2016年   22230篇
  2015年   25042篇
  2014年   35874篇
  2013年   54102篇
  2012年   73848篇
  2011年   77469篇
  2010年   45243篇
  2009年   43245篇
  2008年   73074篇
  2007年   77415篇
  2006年   78125篇
  2005年   76083篇
  2004年   73184篇
  2003年   70654篇
  2002年   69637篇
  2001年   113460篇
  2000年   117554篇
  1999年   99263篇
  1998年   28320篇
  1997年   25856篇
  1996年   25752篇
  1995年   24857篇
  1994年   23389篇
  1993年   21775篇
  1992年   79879篇
  1991年   76807篇
  1990年   74018篇
  1989年   71224篇
  1988年   66180篇
  1987年   65137篇
  1986年   61650篇
  1985年   58693篇
  1984年   44440篇
  1983年   37846篇
  1982年   23003篇
  1981年   20440篇
  1979年   41470篇
  1978年   29120篇
  1977年   24479篇
  1976年   22959篇
  1975年   24092篇
  1974年   29788篇
  1973年   28180篇
  1972年   26374篇
  1971年   24285篇
  1970年   22854篇
  1969年   21219篇
  1968年   19255篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
111.
112.
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).

Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.

Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).

Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).

Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.

Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED.  相似文献   
113.
114.
115.
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris.  相似文献   
116.
117.
118.
119.
120.
This study used the National Survey of Ambulatory Surgery (NSAS) database to measure the incidence of and risk factors for symptoms in the ambulatory surgery center and problems within 24 h after isolated carpal tunnel release (CTR). The NSAS contained records on 400,000 adult patients with carpal tunnel syndrome who were treated with CTR in 2006, based on ICD-9 codes. The type of anesthesia used and factors associated with symptoms and problems were sought in bivariate and multivariable statistical analyses. The mean duration of the procedure was 16 ± 8.8 min. Only 5 % were performed under local anesthesia without sedation, 45 % with IV sedation, 28 % regional anesthesia, and 19 % general anesthesia. Symptoms in the ambulatory surgery center or a problem within 24 h after discharge were recorded in 10 % of patients, all of them minor and transient, including difficulties with pain and its treatment. The strongest risk factors were male sex, age of 45 years and older, and participation of an anesthesiologist. Local anesthesia and regional anesthesia were associated with more perioperative symptoms and postoperative problems. Most CTR are performed with some sedation in the United States. CTR is a safe procedure: one in 10 patients will experience a minor issue in the perioperative or immediate postoperative period.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号